Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NeurAxon Inc.
Mississauga/Toronto, Ontario, Canadaneuraxon.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeurAxon Inc. was a Canadian biotech/pharmaceutical company focused on developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS). Its lead candidate, NXN‑188, combined nNOS inhibition with serotonin receptor agonism for the treatment of acute migraine. The company built a pipeline of first-in-class selective nNOS inhibitors aimed at addressing unmet needs in pain management and potentially other CNS-related conditions. As of the latest available information, NeurAxon had raised nearly $29 million from top-tier investors but has since exited and appears inactive.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- small molecules
- Industry
- Biotech
Beyond the preview
Go deeper on NeurAxon Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeurAxon Inc..